Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two Part First-in-human Phase I Study (With Expanded Cohorts) With the Antibody-drug Conjugate SYD985 to Evaluate the Safety, Pharmacokinetics and Efficacy in Patients With Locally Advanced or Metastatic Solid Tumors

NCT02277717 is registered in ClinicalTrials.gov with Byondis B.V. as lead sponsor.

NCT NCT02277717
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02277717 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two Part First-in-human Phase I Study (With Expanded Cohorts) With the Antibody-drug Conjugate SYD985 to Evaluate the Safety, Pharmacokinetics and Efficacy in Patients With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Byondis B.V.
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2014
Completion date
October 31, 2019
Enrollment
185 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors